Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1 (LENVAMEL)

Centre Hospitalier Universitaire de Besancon

Status: Completed

Conditions: Metastatic Melanoma

Study type: Observational

Funder types: Other

Identifiers

NCT06586580

2023/757

Details and patient eligibility

About

The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate < 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy)

Exclusion criteria

• Uveal melanoma

Trial design

18 participants in 1 patient group

Metastatic melanoma

Description:

Metastatic melanoma refractory to immunotherapy